BBO-10203（又称 Compound 758）是一种可口服的小分子化合物，通过结合 PI3Kα 的 Ras 结合域，选择性地阻断 PI3Kα-Ras 相互作用。BBO-10203 有效阻止 Ras-PI3Kα 复合物形成，并抑制下游 Akt 激活，而不影响基础 PI3Kα 激酶活性，从而降低高血糖与高胰岛素血症风险；BBO-10203对 KRAS 突变肿瘤具有选择性抗肿瘤活性，是靶向癌症研究的重要候选分子。

A-205804 是一种选择性口服有效的先导抑制剂，抑制 E-selectin 和 ICAM-1表达，IC50分别为 20 nM 和 25 nM，可用于慢性炎症疾病的研究。

Tetradecyltrimethylammonium bromide (MitMAB) 是一种具有不对称结构的阳离子表面活性剂，是一种有机结构单元。

N-Desmethyltamoxifen, the principal metabolite of tamoxifen in humans, serves as an efficacious modulator of ceramide metabolism within human AML cells by inhibiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation. Although it demonstrates weak antiestrogenic properties, it acts as a protein kinase C (PKC) inhibitor with a potency ten times greater than that of tamoxifen.

ExcisaninA may be a potent inhibitor of AKT signaling pathway in tumor cells, it can inhibit invasion by suppressing MMP-2 and MMP-9 expression, it may be a potential anti-metastatic chemotherapeutic agent for the treatment of breast cancer. Excisanin A shows comparable inhibitory effects on the LPS-induced production of NO and PGE2, and activation of NF-kappaB without affecting cell viability.Excisanin A induces apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADP-ribose) polymerase (PARP).

Adonixanthin ((3S,3'R)-Adonixanthin) 是一种类胡萝卜素，具备口服活性的抗氧化和抗癌特性。它能有效抑制三种胶质母细胞瘤细胞的增殖与迁移，并通过多种途径提供细胞保护作用，尤其是在抑制活性氧 (ROS) 产生方面表现出色。Adonixanthin 不仅通过抗氧化反应保护细胞，还通过激活Nrf2减少光诱导的损伤。它能够减缓胶质母细胞瘤的进展，并在自体血脑出血 (ICH) 模型中改善血脑屏障的通透性升高。Adonixanthin 适用于胶质母细胞瘤 (GBM) 和脑出血 (ICH) 研究。